Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

Trial Details

NCT ID
NCT06128551
Phase
PHASE1 / PHASE2
Sponsor
Revolution Medicines, Inc.
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Elironrasib
  • Daraxonrasib
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Orange, California, United States|33.78779,-117.85311
  • Sacramento, California, United States|38.58157,-121.4944
  • Stanford, California, United States|37.42411,-122.16608
  • Aurora, Colorado, United States|39.72943,-104.83192

Key Eligibility Criteria

  • 18 years of age
  • Histology: pathologically documented, KRAS G12C-mutated, advanced or metastatic solid tumors not amendable to curative therapy
  • Phase 1b Dose Escalation: solid tumors, previously treated
  • Phase 1b Dose Expansion and Phase 2:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →